Omniose, a St. Louis-based startup developing better ways to make vaccines that fight bacterial infections, has been acquired by the global pharmaceutical and biotech company AstraZeneca.
The two companies made the announcement Tuesday morning, with Omniose becoming a wholly owned subsidiary of AstraZeneca and a part of its Infectious Disease Unit. The announcement did not disclose financial terms.
“The acquisition by AstraZeneca is a great outcome for both organizations. We share a vision for bringing the best science and talent together to address serious bacterial infections, which are increasingly complicated by antimicrobial resistance,” Timothy Cooke, Omniose’s former CEO said in a press release…